Global Hereditary Cancer Testing
Global Hereditary Cancer Testing

Hereditary Cancer Testing Comprehensive Study by Type (Biopsy, Imaging, Others), Application (Breast Cancer, Ovarian Cancer, Colorectal Cancer, Others), End User (Diagnostic Laboratory, Hospitals, Others) Players and Region - Global Market Outlook to 2025

Hereditary Cancer Testing Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 230 Pages 211 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Hereditary Cancer Testing Market?

Genetic testing helps estimate the chance of developing cancer. It does this by searching for specific changes in genes, chromosomes, or proteins. Genetic testing helps to predict the risk of a particular disease, find if genes that may pass have increased cancer risk to children, and provide information to guide health care. Hereditary cancer testing is increasing in its scope and ambition with each year that passes, requiring a greater proportion of the healthcare workforce to acquire a working knowledge of cancer and cancer testing to manage their patients safely and sensitively.

The market study is being classified by Type (Biopsy, Imaging and Others), by Application (Breast Cancer, Ovarian Cancer, Colorectal Cancer and Others) and major geographies with country level break-up.

Ambry Genetics (United States), ARUP Laboratories (United States), Asper Biogene (Estonia), Natera Inc (United States), Caris Life Sciences (United States), BioReference Laboratories (United States), Progenity (United States), NeoGenomics Laboratories, Inc (United States), Blueprint Genetics (Finland), CellMax Life (United States), Fulgent Genetics (United States), Myriad Genetics, Inc. (United States) and Myogenes (United Kingdom) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are LabCorp (United States), Quest Diagnostics (United States) and Pathway Genomics (United States).

The increasing cases of cancer growing the need for its testing tools in the market. The leading firms are coming with newly enhanced products with technological advancements increasing the competition between rivalries. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Hereditary Cancer Testing market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Hereditary Cancer Testing market by Type, Application and Region.

On the basis of geography, the market of Hereditary Cancer Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rising Demand for Non-invasive Techniques for the Detection of Hereditary Cancer
  • Increasing Need for Early Detection and Accurate Diagnosis

Market Trend
  • The Surge in Adoption of Histopathological Detection

Restraints
  • Difficulties in Accessing the Complete Genomic Data for Early Detection and Prevention

Opportunities
  • Increasing Government Funding for Improvement of Rapid Diagnostics
  • Rising Healthcare Spending in Developing Economies

Challenges
  • High Cost Associated With the Tests


Market Leaders and some development strategies
In Dec 2019, Caris Life Sciences® and Ambry Genetics (Ambry) announced that Caris will begin offering Ambry’s 67-gene CancerNext-Expanded panel to evaluate the hereditary risks for cancer. This will be the most comprehensive, clinically relevant molecular and genetic offering on the market to guide the treatment and management of cancer.
In July 2020, Myriad Genetics, Inc. announced a new collaboration with OptraHEALTH® to implement a cognitive ChatBOT named Gene™ to provide genetic and financial assistance information to prospective patients.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Hereditary Cancer Testing Providers, Hereditary Cancer Testing Devices Provider, Suppliers and Distributors of Hereditary Cancer Testing Devices, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations, End-Use Industry and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Biopsy
  • Imaging
  • Others
By Application
  • Breast Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Others
By End User
  • Diagnostic Laboratory
  • Hospitals
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Demand for Non-invasive Techniques for the Detection of Hereditary Cancer
      • 3.2.2. Increasing Need for Early Detection and Accurate Diagnosis
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated With the Tests
    • 3.4. Market Trends
      • 3.4.1. The Surge in Adoption of Histopathological Detection
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hereditary Cancer Testing, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Hereditary Cancer Testing (Value)
      • 5.2.1. Global Hereditary Cancer Testing by: Type (Value)
        • 5.2.1.1. Biopsy
        • 5.2.1.2. Imaging
        • 5.2.1.3. Others
      • 5.2.2. Global Hereditary Cancer Testing by: Application (Value)
        • 5.2.2.1. Breast Cancer
        • 5.2.2.2. Ovarian Cancer
        • 5.2.2.3. Colorectal Cancer
        • 5.2.2.4. Others
      • 5.2.3. Global Hereditary Cancer Testing by: End User (Value)
        • 5.2.3.1. Diagnostic Laboratory
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Others
      • 5.2.4. Global Hereditary Cancer Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Hereditary Cancer Testing (Price)
      • 5.3.1. Global Hereditary Cancer Testing by: Type (Price)
  • 6. Hereditary Cancer Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ambry Genetics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ARUP Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Asper Biogene (Estonia)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Natera Inc (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Caris Life Sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. BioReference Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Progenity (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeoGenomics Laboratories, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Blueprint Genetics (Finland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CellMax Life (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Fulgent Genetics (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Myriad Genetics, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Myogenes (United Kingdom)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Hereditary Cancer Testing Sale, by Type, Application, End User and Region (value and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Hereditary Cancer Testing (Value)
      • 7.2.1. Global Hereditary Cancer Testing by: Type (Value)
        • 7.2.1.1. Biopsy
        • 7.2.1.2. Imaging
        • 7.2.1.3. Others
      • 7.2.2. Global Hereditary Cancer Testing by: Application (Value)
        • 7.2.2.1. Breast Cancer
        • 7.2.2.2. Ovarian Cancer
        • 7.2.2.3. Colorectal Cancer
        • 7.2.2.4. Others
      • 7.2.3. Global Hereditary Cancer Testing by: End User (Value)
        • 7.2.3.1. Diagnostic Laboratory
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Others
      • 7.2.4. Global Hereditary Cancer Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Hereditary Cancer Testing (Price)
      • 7.3.1. Global Hereditary Cancer Testing by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hereditary Cancer Testing: by Type(USD Million)
  • Table 2. Hereditary Cancer Testing Biopsy , by Region USD Million (2015-2020)
  • Table 3. Hereditary Cancer Testing Imaging , by Region USD Million (2015-2020)
  • Table 4. Hereditary Cancer Testing Others , by Region USD Million (2015-2020)
  • Table 5. Hereditary Cancer Testing: by Application(USD Million)
  • Table 6. Hereditary Cancer Testing Breast Cancer , by Region USD Million (2015-2020)
  • Table 7. Hereditary Cancer Testing Ovarian Cancer , by Region USD Million (2015-2020)
  • Table 8. Hereditary Cancer Testing Colorectal Cancer , by Region USD Million (2015-2020)
  • Table 9. Hereditary Cancer Testing Others , by Region USD Million (2015-2020)
  • Table 10. Hereditary Cancer Testing: by End User(USD Million)
  • Table 11. Hereditary Cancer Testing Diagnostic Laboratory , by Region USD Million (2015-2020)
  • Table 12. Hereditary Cancer Testing Hospitals , by Region USD Million (2015-2020)
  • Table 13. Hereditary Cancer Testing Others , by Region USD Million (2015-2020)
  • Table 14. South America Hereditary Cancer Testing, by Country USD Million (2015-2020)
  • Table 15. South America Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 16. South America Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 17. South America Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 18. Brazil Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 19. Brazil Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 20. Brazil Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 21. Argentina Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 22. Argentina Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 23. Argentina Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 24. Rest of South America Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 25. Rest of South America Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 26. Rest of South America Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 27. Asia Pacific Hereditary Cancer Testing, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 29. Asia Pacific Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 30. Asia Pacific Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 31. China Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 32. China Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 33. China Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 34. Japan Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 35. Japan Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 36. Japan Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 37. India Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 38. India Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 39. India Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 40. South Korea Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 41. South Korea Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 42. South Korea Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 43. Taiwan Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 44. Taiwan Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 45. Taiwan Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 46. Australia Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 47. Australia Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 48. Australia Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 52. Europe Hereditary Cancer Testing, by Country USD Million (2015-2020)
  • Table 53. Europe Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 54. Europe Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 55. Europe Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 56. Germany Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 57. Germany Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 58. Germany Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 59. France Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 60. France Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 61. France Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 62. Italy Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 63. Italy Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 64. Italy Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 65. United Kingdom Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 66. United Kingdom Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 67. United Kingdom Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 68. Netherlands Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 69. Netherlands Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 70. Netherlands Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 71. Rest of Europe Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 72. Rest of Europe Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 73. Rest of Europe Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 74. MEA Hereditary Cancer Testing, by Country USD Million (2015-2020)
  • Table 75. MEA Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 76. MEA Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 77. MEA Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 78. Middle East Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 79. Middle East Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 80. Middle East Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 81. Africa Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 82. Africa Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 83. Africa Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 84. North America Hereditary Cancer Testing, by Country USD Million (2015-2020)
  • Table 85. North America Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 86. North America Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 87. North America Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 88. United States Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 89. United States Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 90. United States Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 91. Canada Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 92. Canada Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 93. Canada Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 94. Mexico Hereditary Cancer Testing, by Type USD Million (2015-2020)
  • Table 95. Mexico Hereditary Cancer Testing, by Application USD Million (2015-2020)
  • Table 96. Mexico Hereditary Cancer Testing, by End User USD Million (2015-2020)
  • Table 97. Hereditary Cancer Testing: by Type(USD/Units)
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Hereditary Cancer Testing: by Type(USD Million)
  • Table 112. Hereditary Cancer Testing Biopsy , by Region USD Million (2020-2025)
  • Table 113. Hereditary Cancer Testing Imaging , by Region USD Million (2020-2025)
  • Table 114. Hereditary Cancer Testing Others , by Region USD Million (2020-2025)
  • Table 115. Hereditary Cancer Testing: by Application(USD Million)
  • Table 116. Hereditary Cancer Testing Breast Cancer , by Region USD Million (2020-2025)
  • Table 117. Hereditary Cancer Testing Ovarian Cancer , by Region USD Million (2020-2025)
  • Table 118. Hereditary Cancer Testing Colorectal Cancer , by Region USD Million (2020-2025)
  • Table 119. Hereditary Cancer Testing Others , by Region USD Million (2020-2025)
  • Table 120. Hereditary Cancer Testing: by End User(USD Million)
  • Table 121. Hereditary Cancer Testing Diagnostic Laboratory , by Region USD Million (2020-2025)
  • Table 122. Hereditary Cancer Testing Hospitals , by Region USD Million (2020-2025)
  • Table 123. Hereditary Cancer Testing Others , by Region USD Million (2020-2025)
  • Table 124. South America Hereditary Cancer Testing, by Country USD Million (2020-2025)
  • Table 125. South America Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 126. South America Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 127. South America Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 128. Brazil Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 129. Brazil Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 130. Brazil Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 131. Argentina Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 132. Argentina Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 133. Argentina Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 134. Rest of South America Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 135. Rest of South America Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 136. Rest of South America Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 137. Asia Pacific Hereditary Cancer Testing, by Country USD Million (2020-2025)
  • Table 138. Asia Pacific Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 139. Asia Pacific Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 140. Asia Pacific Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 141. China Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 142. China Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 143. China Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 144. Japan Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 145. Japan Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 146. Japan Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 147. India Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 148. India Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 149. India Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 150. South Korea Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 151. South Korea Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 152. South Korea Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 153. Taiwan Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 154. Taiwan Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 155. Taiwan Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 156. Australia Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 157. Australia Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 158. Australia Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 159. Rest of Asia-Pacific Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 160. Rest of Asia-Pacific Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 161. Rest of Asia-Pacific Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 162. Europe Hereditary Cancer Testing, by Country USD Million (2020-2025)
  • Table 163. Europe Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 164. Europe Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 165. Europe Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 166. Germany Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 167. Germany Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 168. Germany Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 169. France Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 170. France Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 171. France Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 172. Italy Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 173. Italy Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 174. Italy Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 175. United Kingdom Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 176. United Kingdom Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 177. United Kingdom Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 178. Netherlands Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 179. Netherlands Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 180. Netherlands Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 181. Rest of Europe Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 182. Rest of Europe Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 183. Rest of Europe Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 184. MEA Hereditary Cancer Testing, by Country USD Million (2020-2025)
  • Table 185. MEA Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 186. MEA Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 187. MEA Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 188. Middle East Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 189. Middle East Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 190. Middle East Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 191. Africa Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 192. Africa Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 193. Africa Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 194. North America Hereditary Cancer Testing, by Country USD Million (2020-2025)
  • Table 195. North America Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 196. North America Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 197. North America Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 198. United States Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 199. United States Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 200. United States Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 201. Canada Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 202. Canada Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 203. Canada Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 204. Mexico Hereditary Cancer Testing, by Type USD Million (2020-2025)
  • Table 205. Mexico Hereditary Cancer Testing, by Application USD Million (2020-2025)
  • Table 206. Mexico Hereditary Cancer Testing, by End User USD Million (2020-2025)
  • Table 207. Hereditary Cancer Testing: by Type(USD/Units)
  • Table 208. Research Programs/Design for This Report
  • Table 209. Key Data Information from Secondary Sources
  • Table 210. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hereditary Cancer Testing: by Type USD Million (2015-2020)
  • Figure 5. Global Hereditary Cancer Testing: by Application USD Million (2015-2020)
  • Figure 6. Global Hereditary Cancer Testing: by End User USD Million (2015-2020)
  • Figure 7. South America Hereditary Cancer Testing Share (%), by Country
  • Figure 8. Asia Pacific Hereditary Cancer Testing Share (%), by Country
  • Figure 9. Europe Hereditary Cancer Testing Share (%), by Country
  • Figure 10. MEA Hereditary Cancer Testing Share (%), by Country
  • Figure 11. North America Hereditary Cancer Testing Share (%), by Country
  • Figure 12. Global Hereditary Cancer Testing: by Type USD/Units (2015-2020)
  • Figure 13. Global Hereditary Cancer Testing share by Players 2020 (%)
  • Figure 14. Global Hereditary Cancer Testing share by Players (Top 3) 2020(%)
  • Figure 15. Global Hereditary Cancer Testing share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Ambry Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 18. Ambry Genetics (United States) Revenue: by Geography 2020
  • Figure 19. ARUP Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. ARUP Laboratories (United States) Revenue: by Geography 2020
  • Figure 21. Asper Biogene (Estonia) Revenue, Net Income and Gross profit
  • Figure 22. Asper Biogene (Estonia) Revenue: by Geography 2020
  • Figure 23. Natera Inc (United States) Revenue, Net Income and Gross profit
  • Figure 24. Natera Inc (United States) Revenue: by Geography 2020
  • Figure 25. Caris Life Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 26. Caris Life Sciences (United States) Revenue: by Geography 2020
  • Figure 27. BioReference Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. BioReference Laboratories (United States) Revenue: by Geography 2020
  • Figure 29. Progenity (United States) Revenue, Net Income and Gross profit
  • Figure 30. Progenity (United States) Revenue: by Geography 2020
  • Figure 31. NeoGenomics Laboratories, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 32. NeoGenomics Laboratories, Inc (United States) Revenue: by Geography 2020
  • Figure 33. Blueprint Genetics (Finland) Revenue, Net Income and Gross profit
  • Figure 34. Blueprint Genetics (Finland) Revenue: by Geography 2020
  • Figure 35. CellMax Life (United States) Revenue, Net Income and Gross profit
  • Figure 36. CellMax Life (United States) Revenue: by Geography 2020
  • Figure 37. Fulgent Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 38. Fulgent Genetics (United States) Revenue: by Geography 2020
  • Figure 39. Myriad Genetics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Myriad Genetics, Inc. (United States) Revenue: by Geography 2020
  • Figure 41. Myogenes (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. Myogenes (United Kingdom) Revenue: by Geography 2020
  • Figure 43. Global Hereditary Cancer Testing: by Type USD Million (2020-2025)
  • Figure 44. Global Hereditary Cancer Testing: by Application USD Million (2020-2025)
  • Figure 45. Global Hereditary Cancer Testing: by End User USD Million (2020-2025)
  • Figure 46. South America Hereditary Cancer Testing Share (%), by Country
  • Figure 47. Asia Pacific Hereditary Cancer Testing Share (%), by Country
  • Figure 48. Europe Hereditary Cancer Testing Share (%), by Country
  • Figure 49. MEA Hereditary Cancer Testing Share (%), by Country
  • Figure 50. North America Hereditary Cancer Testing Share (%), by Country
  • Figure 51. Global Hereditary Cancer Testing: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Ambry Genetics (United States)
  • ARUP Laboratories (United States)
  • Asper Biogene (Estonia)
  • Natera Inc (United States)
  • Caris Life Sciences (United States)
  • BioReference Laboratories (United States)
  • Progenity (United States)
  • NeoGenomics Laboratories, Inc (United States)
  • Blueprint Genetics (Finland)
  • CellMax Life (United States)
  • Fulgent Genetics (United States)
  • Myriad Genetics, Inc. (United States)
  • Myogenes (United Kingdom)
Additional players considered in the study are as follows:
LabCorp (United States) , Quest Diagnostics (United States) , Pathway Genomics (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation